We offer validated IHC assays for established ADC targets,including HER2,cMET,B7H3,TROP2,DLL3,EGFR,and Nectin2. We're also actively developing assays for emerging targets,including B7-H4,HER3,ROR1,CEACAM5,and STEAP1,with additional biomarkers coming soon.
"},{"faq_question":"How,and to what extent,must the ADC target be expressed on cancer cells? ","faq_answer":"Target expression is a prerequisite for ADC efficacy. The required level and pattern of expression can vary significantly depending on the ADC and the mechanism of action. CellCarta supports expression analysis across multiple platforms — including IHC,IF,flow cytometry,and mass spectrometry — to help you determine the threshold and distribution of target expression needed for your program."},{"faq_question":"What assay technologies are available? ","faq_answer":"Our ADC platform spans singleplex and multiplex IHC,multiplex immunofluorescence with up to 40 markers per slide,in-situ hybridization (ISH/RNAscope),and FISH. This multi-modal approach allows us to characterise target expression at the protein,RNA,and genomic level within the same tissue context. "},{"faq_question":"How do you assess ADC killing of target cells? ","faq_answer":"Assessing ADC killing efficiency requires evaluating multiple downstream events:target engagement,internalization,linker cleavage,and cytotoxic payload release. CellCarta uses receptor occupancy (RO) assays and transcriptomic approaches (RNAseq,CITE-seq) to indirectly assess binding efficiency and payload activity across both solid and non-solid tumors."},{"faq_question":"Does ADC have on-target,off-tumor effects? ","faq_answer":"Identifying on-target,off-tumor toxicity early is critical for safe ADC development. Our mIF and mIHC platforms evaluate target expression in normal tissues,while flow cytometry tracks circulating target-expressing cell counts as a surrogate for off-target killing. Bulk RNA sequencing and gene set enrichment analysis (GSEA) further investigate activated toxicity pathways. "}];oxy-supreme-cellcarta-cta-banner-items-data:[{"faq_question":"What ADC biomarkers do you support?","faq_answer":"We offer validated IHC assays for established ADC targets,including HER2,cMET,B7H3,TROP2,DLL3,EGFR,and Nectin2. We're also actively developing assays for emerging targets,including B7-H4,HER3,ROR1,CEACAM5,and STEAP1,with additional biomarkers coming soon.
"},{"faq_question":"How,and to what extent,must the ADC target be expressed on cancer cells? ","faq_answer":"Target expression is a prerequisite for ADC efficacy. The required level and pattern of expression can vary significantly depending on the ADC and the mechanism of action. CellCarta supports expression analysis across multiple platforms — including IHC,IF,flow cytometry,and mass spectrometry — to help you determine the threshold and distribution of target expression needed for your program."},{"faq_question":"What assay technologies are available? ","faq_answer":"Our ADC platform spans singleplex and multiplex IHC,multiplex immunofluorescence with up to 40 markers per slide,in-situ hybridization (ISH/RNAscope),and FISH. This multi-modal approach allows us to characterise target expression at the protein,RNA,and genomic level within the same tissue context. "},{"faq_question":"How do you assess ADC killing of target cells? ","faq_answer":"Assessing ADC killing efficiency requires evaluating multiple downstream events:target engagement,internalization,linker cleavage,and cytotoxic payload release. CellCarta uses receptor occupancy (RO) assays and transcriptomic approaches (RNAseq,CITE-seq) to indirectly assess binding efficiency and payload activity across both solid and non-solid tumors."},{"faq_question":"Does ADC have on-target,off-tumor effects? ","faq_answer":"Identifying on-target,off-tumor toxicity early is critical for safe ADC development. Our mIF and mIHC platforms evaluate target expression in normal tissues,while flow cytometry tracks circulating target-expressing cell counts as a surrogate for off-target killing. Bulk RNA sequencing and gene set enrichment analysis (GSEA) further investigate activated toxicity pathways. "}]}#-supreme-cellcarta-faq-13-144{items-data:[{"faq_question":"Quels biomarqueurs ADC prenez-vous en charge ?","faq_answer":"Nous proposons des tests IHC validés pour les cibles ADC établies,notamment HER2,cMET,B7H3,TROP2,DLL3,EGFR et Nectin2. Nous développons également activement des tests pour des cibles émergentes,notamment B7-H4,HER3,ROR1,CEACAM5 et STEAP1,avec d'autres biomarqueurs àvenir prochainement.
"},{"faq_question":"Comment,et dans quelle mesure,la cible de l'ADC doit-elle être exprimée sur les cellules cancéreuses ?","faq_answer":"L'expression de la cible est un prérequis àl'efficacitéde l'ADC. Le niveau et le profil d'expression requis peuvent varier considérablement selon l'ADC et son mécanisme d'action. CellCarta prend en charge l'analyse de l'expression sur de multiples plateformes —notamment l'IHC,l'IF,la cytométrie en flux et la spectrométrie de masse —pour vous aider àdéterminer le seuil et la distribution d'expression de la cible nécessaires àvotre programme de plateforme ADC.
"},{"faq_question":"Quelles technologies de test sont disponibles ?","faq_answer":"Notre offre ADC couvre l'IHC simplex et multiplex,l'immunofluorescence multiplexe avec jusqu'à40 marqueurs par lame,l'hybridation in situ (ISH/RNAscope) et la spectrométrie de masse. Cette approche multimodale nous permet de caractériser l'expression de la cible aux niveaux protéique,ARN et génomique,au sein du même contexte tissulaire,favorisant ainsi l'avancement de la plateforme ADC de votre programme.
"},{"faq_question":"Comment évaluez-vous la destruction des cellules cibles par l'ADC ?","faq_answer":"L'évaluation de l'efficacitéde destruction de l'ADC nécessite d'évaluer plusieurs événements en aval :l'engagement de la cible,l'internalisation,le clivage du lieur et la libération de la charge cytotoxique. CellCarta utilise divers tests,notamment les tests d'occupation des récepteurs (RO),ainsi que des approches (RNAseq,CITE-seq) pour évaluer àla fois l'efficacitéde liaison et l'activitéde la charge utile dans les échantillons tissulaires et liquides.
"},{"faq_question":"L'ADC présente-t-il des effets on-target,off-tumor ?","faq_answer":"Identifier précocement la toxicitéon-target,off-tumor est essentiel pour un développement sûr de la plateforme ADC. Nos plateformes mIF et mIHC évaluent l'expression de la cible dans les tissus normaux,tandis que la cytométrie en flux suit le nombre de cellules circulantes exprimant la cible,en tant que marqueur de substitution de la destruction hors cible. Le séquençage d'ARN en vrac et l'analyse d'enrichissement d'ensembles de gènes (GSEA) permettent d'approfondir l'étude des voies de toxicitéactivées.
"}]}#-supreme-cellcarta-featured-resources-16-144{cards-data:[{"image_url":"\/wp-content\/uploads\/2026\/05\/webinar.jpg","card_type":"Webinar","date":"Feb 12","reading_time":"Reading Time - 5 minutes","title":"Resources Title Goes Here","description":"Lorem ipsum dolor sit amet,consectetuer adipiscing elit. Aenean commodo ligula eget dolor.","url":"#"},{"image_url":"\/wp-content\/uploads\/2026\/05\/webinar-2.jpg","card_type":"Webinar","date":"Feb 12","reading_time":"Reading Time - 5 minutes","title":"Resources Title Goes Here","description":"Lorem ipsum dolor sit amet,consectetuer adipiscing elit. Aenean commodo ligula eget dolor.","url":"#"},{"image_url":"\/wp-content\/uploads\/2026\/05\/webinar-3.jpg","card_type":"Webinar","date":"Feb 12","reading_time":"Reading Time - 5 minutes","title":"Resources Title Goes Here","description":"Lorem ipsum dolor sit amet,consectetuer adipiscing elit. Aenean commodo ligula eget dolor.","url":"#"}]}#-supreme-cellcarta-infobox-24-176{tabs-data:[{"tab_title":"Confirm Target Engagement ","content_title":"","content_body":"Depending on your study,we can incorporate multiple ADC assays to measure target engagement.
\nReceptor occupancy assays and transcriptomic analysis confirm target binding,with continuous image scoring and analysis for clinical endpoints. For early-stage programs,we also support reagent-free mass spectrometry.
\nImmunohistochemistry (IHC) assays can assess expression in solid tumor tissue,while flow cytometry is suited for liquid biopsies.
","tab_image":"https://cellcarta.com/wp-content/uploads/2026/06/Validate-Target-Engagement-133.jpg","image_alt":""},{"tab_title":"Map the TME","content_title":"","content_body":"We can support mapping of the tumor microenvironment (TME),critical for understanding patient response to ADC platforms.
\nTo assess immune cell populations and guide patient selection,we can use various platforms,such as multiplex IHC,CITE-seq,bulk RNAseq,and flow cytometry.
\nOur advanced spatial platforms —Visium,GeoMx,COMET —can layer in added proteomic and genomic analysis to explore cellular phenotype,distribution,and function.
","tab_image":"https://cellcarta.com/wp-content/uploads/2026/07/Lunaphore-COMET.png","image_alt":""},{"tab_title":"Track Stability and Toxicity","content_title":"","content_body":"Track ADC stability and concentration through our advanced mass spectrometry-based workflow,capable of supporting all stages of therapeutic development.
\nFor toxicity,we can assess target expression in normal tissues via mIF and mIHC,track circulating target expressing cells by flow cytometry,and investigate toxicity pathways through bulk RNA sequencing and gene set enrichment analysis.
","tab_image":"https://cellcarta.com/wp-content/uploads/2026/06/Manage-Toxicity-96.jpg","image_alt":""},{"tab_title":"Biobank and Global Presence","content_title":"","content_body":"Accelerate assay development and validation with access to our regulated Biobank,containing over 5,000 consent confirmed and quality checked FFPE and blood samples. This enables immediate study initiation without delay.
\nWhen your ADC platform program is ready to scale,our fully owned and accredited laboratory network across the US,Canada,Belgium,China,and Australia gives you standardized workflows and end-to-end CDx services globally.
","tab_image":"https://cellcarta.com/wp-content/uploads/2026/06/Biobank-176.jpg","image_alt":""}];oxy-supreme-cellcarta-infobox-tabs-data:[{"tab_title":"Confirm Target Engagement ","content_title":"","content_body":"Depending on your study,we can incorporate multiple ADC assays to measure target engagement.
\nReceptor occupancy assays and transcriptomic analysis confirm target binding,with continuous image scoring and analysis for clinical endpoints. For early-stage programs,we also support reagent-free mass spectrometry.
\nImmunohistochemistry (IHC) assays can assess expression in solid tumor tissue,while flow cytometry is suited for liquid biopsies.
","tab_image":"https://cellcarta.com/wp-content/uploads/2026/06/Validate-Target-Engagement-133.jpg","image_alt":""},{"tab_title":"Map the TME","content_title":"","content_body":"We can support mapping of the tumor microenvironment (TME),critical for understanding patient response to ADC platforms.
\nTo assess immune cell populations and guide patient selection,we can use various platforms,such as multiplex IHC,CITE-seq,bulk RNAseq,and flow cytometry.
\nOur advanced spatial platforms —Visium,GeoMx,COMET —can layer in added proteomic and genomic analysis to explore cellular phenotype,distribution,and function.
","tab_image":"https://cellcarta.com/wp-content/uploads/2026/07/Lunaphore-COMET.png","image_alt":""},{"tab_title":"Track Stability and Toxicity","content_title":"","content_body":"Track ADC stability and concentration through our advanced mass spectrometry-based workflow,capable of supporting all stages of therapeutic development.
\nFor toxicity,we can assess target expression in normal tissues via mIF and mIHC,track circulating target expressing cells by flow cytometry,and investigate toxicity pathways through bulk RNA sequencing and gene set enrichment analysis.
","tab_image":"https://cellcarta.com/wp-content/uploads/2026/06/Manage-Toxicity-96.jpg","image_alt":""},{"tab_title":"Biobank and Global Presence","content_title":"","content_body":"Accelerate assay development and validation with access to our regulated Biobank,containing over 5,000 consent confirmed and quality checked FFPE and blood samples. This enables immediate study initiation without delay.
\nWhen your ADC platform program is ready to scale,our fully owned and accredited laboratory network across the US,Canada,Belgium,China,and Australia gives you standardized workflows and end-to-end CDx services globally.
","tab_image":"https://cellcarta.com/wp-content/uploads/2026/06/Biobank-176.jpg","image_alt":""}]}#-supreme-cellcarta-service-blocks-45-176{blocks-data:[{"image":"https://cellcarta.com/wp-content/uploads/2026/06/Sample-Logistics-tab-408.jpg","image_alt":"","title":"Logistique des échantillons","description":"Gestion mondiale des échantillons,services de transport et de biorépertoire avec suivi en temps réel.","button_text":"Découvrir la logistique des échantillons","button_url":"/fr/services-essais-cliniques/gestion-logistique-des-echantillons/","button_target":"_self"},{"image":"https://cellcarta.com/wp-content/uploads/2026/07/21-Biomarker-Solutions-Hero.jpg","image_alt":"","title":"Solutions de biomarqueurs","description":"Des stratégies de biomarqueurs multi-plateformes,de la découverte au développement clinique.","button_text":"Découvrir les solutions de biomarqueurs","button_url":"/fr/capacites/biomarqueurs-cliniques/","button_target":"_self"},{"image":"https://cellcarta.com/wp-content/uploads/2026/06/CDx-Development-hero-64.jpg","image_alt":"","title":"Développement de CDx","description":"Faites progresser vos tests d'essais cliniques vers des programmes CDx approuvés et viables commercialement,avec une flexibilité inégalée.","button_text":"Découvrir les solutions CDx","button_url":"/fr/services-essais-cliniques/developpement-cdx/","button_target":"_self"}]}#-supreme-cellcarta-tab-content-11-144{tabs-data:[{"tab_title":"Confirmer l'engagement de la cible","content_title":"","content_body":"Selon votre étude,nous pouvons intégrer plusieurs tests ADC pour mesurer l'engagement de la cible.
\nLes tests d'occupation des récepteurs et l'analyse transcriptomique confirment la liaison àla cible,avec une notation et une analyse d'images continues pour les critères d'évaluation cliniques. Pour les programmes en phase précoce,nous proposons également la spectrométrie de masse sans réactif.
\nLes tests d'immunohistochimie (IHC) permettent d'évaluer l'expression dans les tissus tumoraux solides,tandis que la cytométrie en flux est adaptée aux biopsies liquides.
","tab_image":"https://cellcarta.com/wp-content/uploads/2026/06/Validate-Target-Engagement-133.jpg","image_alt":""},{"tab_title":"Cartographier le TME","content_title":"","content_body":"Nous pouvons soutenir la cartographie du microenvironnement tumoral (TME),essentielle pour comprendre la réponse des patients aux plateformes ADC.
\nPour évaluer les populations de cellules immunitaires et orienter la sélection des patients,nous pouvons utiliser diverses plateformes,telles que l'IF multiplexe (mIF),la mIHC,le CITE-seq,le RNAseq en vrac et la cytométrie en flux.
\nNos plateformes spatiales avancées —Visium,GeoMx,COMET —permettent d'ajouter des analyses protéomiques et génomiques supplémentaires afin d'explorer le phénotype,la distribution et la fonction cellulaires.
","tab_image":"https://cellcarta.com/wp-content/uploads/2026/07/Lunaphore-COMET.png","image_alt":""},{"tab_title":"Suivre la stabilité et la toxicité","content_title":"","content_body":"Suivez la stabilitéet la concentration de l'ADC grâce ànotre flux de travail avancébasésur la spectrométrie de masse,capable de soutenir toutes les étapes du développement thérapeutique.
\nPour la toxicité,nous pouvons évaluer l'expression de la cible dans les tissus normaux via la mIF et la mIHC,suivre les cellules circulantes exprimant la cible par cytométrie en flux,et étudier les voies de toxicitépar séquençage d'ARN en vrac et analyse d'enrichissement d'ensembles de gènes.
","tab_image":"https://cellcarta.com/wp-content/uploads/2026/06/Manage-Toxicity-96.jpg","image_alt":""},{"tab_title":"Biobanque et infrastructure mondiale","content_title":"","content_body":"Accélérez le développement et la validation des tests grâce àun accès direct ànotre biobanque réglementée,contenant plus de 5000 échantillons FFPE et sanguins dont le consentement est confirméet la qualitévérifiée. Cela permet un démarrage immédiat de l'étude,sans délai.
\nLorsque votre programme de plateforme ADC est prêt àêtre déployéàgrande échelle,notre réseau de laboratoires entièrement détenus et accrédités aux États-Unis,au Canada,en Belgique,en Chine et en Australie vous offre des flux de travail standardisés et des services CDx de bout en bout àl'échelle mondiale.
","tab_image":"https://cellcarta.com/wp-content/uploads/2026/06/Biobank-176.jpg","image_alt":""}]}